Statins: Overview
What it does
The job the technology does for people, in a short paragraph
Statins lower the LDL cholesterol in the blood that builds up in artery walls, and so cut heart attacks and strokes [1]. Across 14 trials they reduced heart attacks by 25 to 30% [1]. The first was approved in 1987 [1]. In 41 low- and middle-income countries, about 8% of eligible adults used one for primary prevention in surveys from 2013 to 2019 [4].
as of 2026-11-11
How it works
The working principle in plain words, step by step
The body gets cholesterol from food and makes much of its own, mostly in the liver [1, 2]. One step on that production line is run by an enzyme, HMG-CoA reductase, which turns a molecule called HMG-CoA into mevalonate [3]. A statin molecule fits the enzyme and blocks it, so the liver makes less cholesterol [3]. Short of cholesterol, liver cells put more LDL receptors on their surface [2, 3]. These receptors catch LDL particles, the main carriers of cholesterol in the blood, and pull them into the cell [2]. The level of LDL in the blood falls, and less of it is left to form the fatty deposits that narrow blood vessels [1].
as of 2026-11-11
Key figures
The handful of numbers that size it up, each with its unit, year and source
| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Fall in LDL cholesterol with simvastatin in the 4S trial | 35 | % | 1994 | [1] |
| Fall in coronary heart disease deaths in the 4S trial | 40 | % | 1994 | [1] |
| Statin use for primary prevention among eligible adults in 41 low- and middle-income countries | 8 | % | 2019 | [4] |
| Statin use for secondary prevention in the same countries | 21.9 | % | 2019 | [4] |
| LDL cholesterol lowering with high-intensity statin treatment (more than) | 50 | % | 2024 | [3] |
as of 2026-11-11. The 41-country figures come from surveys carried out between 2013 and 2019 [4]; the year shown is the end of that period. The 4S rows carry 1994, the year the trial results were reported [1]. The high-intensity row carries 2024, the update year of source 3, a publication year, not a data year.
Where it is used
The main places and products the technology is found in
- Prevention of heart attacks and strokes in people at high risk (primary prevention)
- Treatment after a heart attack or stroke to prevent another (secondary prevention)
- Inherited high cholesterol
- Prescribed in general practice and hospital clinics, taken as daily tablets
as of 2026-11-11
Scale today
How much of it there is now: units in use, made each year and who uses it
- Users
- An estimated 30 million people worldwide [1, 6]; no newer world count was found
- Unit
- people taking statins
- Year
- 2008
- Note
- The 30 million figure appears in the 2008 Lasker award text and again in Endo's 2010 review; 2008 is a publication year, not a data year. Use in poorer countries remains low, about 8% of eligible adults for prevention [4].
as of 2026-11-11
Sources
- Statins for lowering LDL and decreasing heart attacks Lasker Foundation (text of the 2008 Lasker-DeBakey Clinical Medical Research Award to Akira Endo), 2008
- The Nobel Prize in Physiology or Medicine 1985 - Press release Nobel Assembly at Karolinska Institutet, 1985
- Statin Medications StatPearls (NCBI Bookshelf), last updated 29 February 2024, 2024
- Use of statins for the prevention of cardiovascular disease in 41 low- and middle-income countries: a cross-sectional study of nationally representative, individual-level data The Lancet Global Health 10(3):e369-e379 (Marcus and others), record at the University of Birmingham, 2022
- A historical perspective on the discovery of statins Proceedings of the Japan Academy, Series B 86(5):484-493 (Akira Endo), on PubMed Central, 2010